Online citations, reference lists, and bibliographies.
← Back to Search

Improved Diagnosis And Prognostication Of Patients With Pleural Malignant Mesothelioma Using Biomarkers In Pleural Effusions And Peripheral Blood Samples – A Short Report

Nick Beije, J. Kraan, M. D. den Bakker, A. Maat, C. van der Leest, R. Cornelissen, N. M. Van, J. Martens, J. Aerts, S. Sleijfer
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PurposeThere is a lack of robust and clinically utilizable markers for the diagnosis and prognostication of malignant pleural mesothelioma (MPM). This research was aimed at optimizing and exploring novel approaches to improve the diagnosis and prognostication of MPM in pleural effusions and peripheral blood samples.MethodsCellSearch-based and flow cytometry-based assays using melanoma cell adhesion molecule (MCAM) to identify circulating tumor cells (CTCs) in pleural effusions and peripheral blood samples of MPM patients were optimized, validated, explored clinically and, in case of pleural effusions, compared with cytological analyses. Additionally, tumor-associated circulating endothelial cells (CECs) were measured in peripheral blood samples. The assays were performed on a MPM cohort encompassing patients with histology-confirmed MPM (n=27) and in a control cohort of patients with alternative diagnoses (n=22). Exploratory analyses on the prognostic value of all assays were also performed.ResultsThe malignancy of MCAM-positive cells in pleural effusions from MPM patients was confirmed. The detection of MPM CTCs in pleural effusions by CellSearch showed a poor specificity. The detection of MPM CTCs in pleural effusions by flow cytometry showed a superior sensitivity (48%) to standard cytological analysis (15%) (p = 0.03). In peripheral blood, CTCs were detected in 26% of the MPN patients, whereas in 42% of the MPM patients tumor-associated CECs were detected above the upper limit of normal (ULN). In exploratory analyses the absence of CTCs in pleural effusions, and tumor-associated CECs in peripheral blood samples above the ULN, appeared to be associated with a worse overall survival.ConclusionMCAM-based flow cytometric analysis of pleural effusions is more sensitive than routine cytological analysis. Flow cytometric analysis of pleural effusions and tumor-associated CECs in peripheral blood may serve as a promising approach for the prognostication of MPM patients and, therefore, warrants further study.
This paper references
10.1158/1078-0432.CCR-08-0872
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
J. D. de Bono (2008)
10.1097/00000478-200009000-00001
The separation of benign and malignant mesothelial proliferations.
A. Churg (2000)
10.1016/S1470-2045(14)70069-5
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
F. Bidard (2014)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1038/modpathol.2010.134
Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium
A. Sato (2010)
10.1016/j.drudis.2012.01.011
Clinical value of circulating endothelial cell detection in oncology.
J. Kraan (2012)
10.1016/j.trsl.2015.04.006
Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis.
A. Nguyen (2015)
10.1245/s10434-013-3399-2
Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM)
K. Yoneda (2013)
10.1513/AnnalsATS.201303-068OC
Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.
Daniel E Schwed Lustgarten (2013)
10.1055/s-0031-1272874
Update on malignant pleural mesothelioma.
N. Campbell (2011)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
Lake, Malignant mesothelioma
B. W. Robinson (2005)
Circulating tumor cells (CTCs) in malignant pleural mesothelioma
K. Yoneda (2014)
10.1093/ANNONC/MDY298.004
A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies.
T. Stinchcombe (2018)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1007/s10549-010-0879-y
Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146
B. Mostert (2010)
10.1245/s10434-012-2506-0
Circulating Endothelial Cell (CEC) as a Diagnostic and Prognostic Marker in Malignant Pleural Mesothelioma (MPM)
K. Yoneda (2012)
10.1158/1535-7163.MCT-14-0653
Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
W. Onstenk (2014)
Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM)
米田 和恵 (2013)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1097/PAT.0b013e32835bc848
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
A. Segal (2013)
10.1158/0008-5472.CAN-08-1363
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.
S. Bidlingmaier (2009)
10.1111/j.1538-7836.2012.04681.x
A new approach for rapid and reliable enumeration of circulating endothelial cells in patients
J. Kraan (2012)
10.1016/J.YPAT.2012.10.023
Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma
A. McCullough (2013)
Detection of circulating tumor cells in breast cancer may improve through enrichment with anti - CD 146
J. Kraan Mostert
10.1038/bjc.2014.286
Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells
J. Kraan (2014)
10.1016/j.bjorl.2017.06.001
The meta-analysis.
F. Ribeiro (2017)
10.1016/j.amjsurg.2008.06.038
Attrition of categoric general surgery residents: results of a 20-year audit.
W. Longo (2009)
10.1378/chest.11-3204
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Rhian S Finn (2012)
Identification of MCAM / CD 146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and Sarcomatoid types of mesothelio
J. He Bidlingmaier (2009)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1200/JCO.2007.15.8923
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
S. Cohen (2008)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1002/dc.21303
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
E. Rakha (2010)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.5858/arpa.2015-0240-SA
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
a prospective study of 188 consecutive patients
Boutin (1993)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1007/s13277-015-4063-1
Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma
H. Liu (2015)
ESMO clinical practice guidelines for diagnosis, treatment and follow-up
P. Baas (2015)
are we there yet? Arch
Churg (2016)
Update on malignant pleural mesothelio
H. Kindler Campbell (2011)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1038/bjc.2015.191
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
N. Beije (2015)
10.3233/CBM-140448
Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
J. Raphael (2015)
10.1371/journal.pone.0072030
Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
Filip Mundt (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar